This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michelle M.

A University of Arizona College of Medicine – Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy ...

Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

Taking the medication mavacamten for HCM can reduce obstruction in your heart. Learn about its benefits, risks, and side ...

The number of patients diagnosed with cardiomyopathy has increased substantially over the past two decades. This is the ...

University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a mouse ...

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and impacts an estimated 1 in 500 people in the U.S., according to the American Heart Association, a relentless force ...